Year All202620252024202320222021202020192018201720162015201420132012201120102007 04.14.20 Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting WALTHAM, Mass. , April 14, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced three presentations at the upcoming 2020 American Read More 03.03.20 Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q20; potential NDA filing later this year - - Phase 1 data presentation from AUGMENT-101 trial of SNDX-5613 in acute leukemias expected 4Q20; potential for interim results throughout 2020 - - SNDX-6352 Read More 02.25.20 Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020 WALTHAM, Mass. , Feb. 25, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2019 Read More 02.18.20 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two Read More 01.31.20 Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million - Offering led by premier life sciences investors including BVF, Boxer Capital and AI Life Sciences - - Shares offered at $8, a 20% premium to the January 30, 2020 market close - - Agreement with Hercules would provide Company with additional, non-dilutive capital to advance its innovative pipeline Read More 01.30.20 Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia - Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals' lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML - WALTHAM, Mass. , Jan. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. Read More 01.10.20 Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook - Final OS analysis for pivotal Phase 3 E2112 trial in HR+, HER2- breast cancer expected 2Q20 - - Phase 1 data presentation from AUGMENT-101 trial of SNDX-5613 in acute leukemias expected 4Q20; potential for interim results throughout 2020- - SNDX-6352 Phase 2 expansion trial in cGVHD initiated; Read More 12.10.19 Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease - Preliminary Phase 1 results demonstrate inhibition of CSF1R leads to responses in patients with cGvHD - - Phase 2 expansion expected to commence in 1Q20 - WALTHAM, Mass. , Dec. 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical Read More 12.09.19 Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias - Data provide detailed look at potential underlying mechanism of action within cells - - Results support ongoing development of SNDX-5613, Company's lead highly selective Menin inhibitor, for treatment of MLL-rearranged acute leukemias - WALTHAM, Mass. , Dec. Read More 11.07.19 Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20 - - First patient dosed in Phase 1/2 AUGMENT-101 trial of SNDX-5613, Company's highly selective Menin inhibitor, for treatment of MLL-rearranged acute leukemias and NPM1-mutant AML - - Company Read More 11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias - Company expects to report initial clinical data in 2020 - WALTHAM, Mass. , Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced Read More 10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019 WALTHAM, Mass. , Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 financial Read More
04.14.20 Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting WALTHAM, Mass. , April 14, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced three presentations at the upcoming 2020 American Read More
03.03.20 Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update - Final OS analysis for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q20; potential NDA filing later this year - - Phase 1 data presentation from AUGMENT-101 trial of SNDX-5613 in acute leukemias expected 4Q20; potential for interim results throughout 2020 - - SNDX-6352 Read More
02.25.20 Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020 WALTHAM, Mass. , Feb. 25, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2019 Read More
02.18.20 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two Read More
01.31.20 Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million - Offering led by premier life sciences investors including BVF, Boxer Capital and AI Life Sciences - - Shares offered at $8, a 20% premium to the January 30, 2020 market close - - Agreement with Hercules would provide Company with additional, non-dilutive capital to advance its innovative pipeline Read More
01.30.20 Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia - Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals' lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML - WALTHAM, Mass. , Jan. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. Read More
01.10.20 Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook - Final OS analysis for pivotal Phase 3 E2112 trial in HR+, HER2- breast cancer expected 2Q20 - - Phase 1 data presentation from AUGMENT-101 trial of SNDX-5613 in acute leukemias expected 4Q20; potential for interim results throughout 2020- - SNDX-6352 Phase 2 expansion trial in cGVHD initiated; Read More
12.10.19 Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease - Preliminary Phase 1 results demonstrate inhibition of CSF1R leads to responses in patients with cGvHD - - Phase 2 expansion expected to commence in 1Q20 - WALTHAM, Mass. , Dec. 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical Read More
12.09.19 Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias - Data provide detailed look at potential underlying mechanism of action within cells - - Results support ongoing development of SNDX-5613, Company's lead highly selective Menin inhibitor, for treatment of MLL-rearranged acute leukemias - WALTHAM, Mass. , Dec. Read More
11.07.19 Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update - E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20 - - First patient dosed in Phase 1/2 AUGMENT-101 trial of SNDX-5613, Company's highly selective Menin inhibitor, for treatment of MLL-rearranged acute leukemias and NPM1-mutant AML - - Company Read More
11.06.19 Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias - Company expects to report initial clinical data in 2020 - WALTHAM, Mass. , Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced Read More
10.31.19 Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019 WALTHAM, Mass. , Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 financial Read More